This is an official statement of the American Association of Diabetes Educators (AADE). AADE is a multidisciplinary professional membership organization of health care professionals dedicated to integrating successful self-management as a key outcome in the care of people with diabetes and related conditions.
Introduction
A formulary is an official list of medications or medical devices that may be prescribed. For the purpose of this paper, medical devices include syringes, insulin pens, insulin pumps, insulin patches, blood glucose meters, blood glucose strips, lancets, and continuous glucose sensors. The purpose of a formulary is to optimize appropriate and efficient utilization of medications, with consideration for cost, efficacy, and safety. 1 Rising costs of medications and medical devices are in part due to the development of new biologic agents, research and development of specialty medications, technology-based insulin pumps and devices, along with the rising prevalence of diabetes in the aged. 2 In addition to the increased cost of medication and medical devices, the recent surge in the number of medical devices and diabetes medications along with multiple formulations of medications in the same class presents a unique challenge to formulary selection and management. Technologies such as insulin delivery devices and continuous glucose monitoring systems are changing rapidly, creating a challenging environment for people with diabetes and providers to determine the diabetes management 
Background
Health insurance formularies have grown over time from simple medication lists to complex medication and medical device formularies with specialty "tiers" and shared cost burden. 5 Formulary composition and variations are also health system or company specific, creating greater complexity. In tiered formularies, medications are placed into categories, or tiers, based on lower-cost preferred drugs, higher-cost nonpreferred drugs, quantity restrictions, and copay amounts. Medicare prescription drug plans are examples of tiered drug formularies. 6 Costs for medications and medical devices will vary for people with diabetes depending on their health insurance coverage and associated out-of-pocket costs, including deductibles, coinsurance, copayments, and noncovered items.
Health systems, such as institutional and ambulatory care settings, are incentivized to use formularies due to reimbursement eligibility requirements from Medicare as well as accreditation requirements from The Joint Commission. 7 The highest cost "nonpreferred" medications may require preapproval from a health insurance plan to authorize payment. These preapproval or prior authorization procedures differ among insurers and can be extremely time-consuming. They often require written proof that the medication was not effective or the formulary medication is not appropriate. 8 
Formulary Decisions
Experts suggest it is most beneficial if a multifaceted "value-based" approach is used to determine which medications and devices will and will not be provided on a formulary. 9 Factors such as the quality of clinical data (efficacy, clinical performance, magnitude of effect), cost-effectiveness, likelihood of severe adverse effects, and overall budget impact should all be taken into account. 9, 10 Device accuracy, ease of use, downloading capability (if applicable), ease of data interpretation, ability to customize, patient perception of device accuracy, and other factors based on the specific device should be considered. Usability barriers of both monitoring and delivery devices due to physical or cognitive limitations must also be factored into decision making.
Within a health system, a Pharmacy and Therapeutics committee can be comprised of physicians, pharmacists, nurses, administrators, and other staff involved in the prescription of medications and/or devices. In addition to creating and maintaining the formulary, the Pharmacy and Therapeutics committee conducts medication use evaluations, adverse drug event monitoring and reporting, medication error prevention, and development of local clinical guidelines. 7 Formulary decision making is guided by current clinical practice guidelines, unbiased review of the biomedical literature, and a focus on providing the most effective and safest patient care. While economic factors play an important role to reduce costs for the health system, it is not recommended that they solely guide drug and device selection.
11
Most health systems have policies that allow for generic or nonbranded substitution or therapeutic interchange, such as switching a prescribed nonformulary medication to a formulary medication within the same therapeutic class, thus providing significant cost savings. Health systems have processes for additions and deletions to the formulary as well as a process to obtain nonformulary medications when the formulary medication is not the most effective choice for a person with diabetes due to adverse effects, allergies, lack of therapeutic response, or other reasons. 7 
Implications of Tiered Formularies
There is limited evidence that medication/device formularies and other cost-saving measures implemented by health insurance companies actually reduce spending, and in fact, they may actually worsen clinical outcomes.
1 A systematic review assessing the impact of medication formularies identified unintentional negative outcomes, including reduced medication adherence and poorer clinical outcomes. 1 One review showed that spending by insurance companies decreased by 5% to 20% with the implementation of a tiered copayment system 12 ; however, this came at the expense of increased cost to the person with diabetes (by up to 148%) and reduced utilization. Data regarding utilization of other health care resources and other clinical outcomes are indeterminate. 8, 12 With an increase in the availability of more costly drug classes, including incretin-based therapies, inhaled insulin, insulin analogs, and sodium-glucose cotransporter-2 (SGLT2) inhibitors, people with diabetes may be negatively affected by tiered formularies. Moreover, different adverse event profiles and drug-drug and/or drug-disease interactions exist with varying diabetes drug classes and between drugs within a class, thus people with diabetes may be vulnerable to formulary restrictions. 13 Advances in insulin delivery devices, continuous glucose monitors, and integrated systems may greatly benefit people with diabetes but may be restricted based on a tiered system.
Despite the existence of a national formulary used among 139 facilities of the Department of Veterans Affairs (VA), a study of diabetes prescribing patterns within the VA system found great variation in the use of a medication not on the national formulary.
14 While formularies guide prescriber medication and device selection, other outside factors may impact prescribing patterns such as number of subspecialties in the practice and providers that are more engaged in diabetes research.
Any decision to restrict a medication or device from the health system or health insurance formulary should not prevent access to medically necessary therapeutic options. Any diabetes medication or device formulary should include at least one medication or device from each class approved by the Food and Drug Administration (FDA) with the agreement that a documented failed product within a class of medications creates an option to trial another option within that class.
The Role of the Diabetes Educator
Because of the depth of both patient-centered knowledge and diabetes medications and devices, diabetes educators are uniquely positioned to advise formulary decision makers. For example, a cumbersome multistep injection device may be associated with lower cost, but the burden of use could impact patient engagement.
The diabetes educator who serves as a member or expert consultant to health system Pharmacy and Therapeutics committees should be actively practicing in the area of diabetes and experienced with medications and devices used by people with diabetes. Decisions made by individuals and groups less connected to the management of diabetes can lead to poor blood glucose results, increased short-and long-term complications, and compromised safety, yielding high financial costs to the individual's health and/or health plan or health care system. 15 If selected to serve as an expert consultant or member of the Pharmacy and Therapeutics committee, the diabetes educator should disclose any financial conflicts and abstain from the decision-making process regarding medications and devices that may pose a conflict of interest.
Conclusion
Diabetes educators are uniquely qualified to contribute to diabetes formulary and medical device decisions. Diabetes educators should serve as expert consultants on Pharmacy and Therapeutics committees for formulary decisions related to diabetes medications and medical devices. Additionally, when a formulary change necessitates a change in medication regimen or device, diabetes educators are well equipped to play a critical role in providing necessary information and training to people with diabetes, health care professionals, and health systems about the integration of new medications or devices for safe and effective transition.
The American Association of Diabetes Educators supports the role of diabetes educators in diabetes formulary and medical device decisions and changes through:
1. providing diabetes expert representation on Pharmacy and Therapeutics committees with diabetes medication and device-related decisions; 2. advocating for people with diabetes affected by formulary changes (including changes in insulin delivery devices, glucose meters, and sensors) by raising awareness via social media, educating patients to self-advocate, and serving on decision-making committees; 3. disseminating information and training to health plans and government agencies regarding the impact of their decisions on diabetes self-care management and support; 4. participating in research related to formulary decisions and the clinical and economic impact of these decisions.
